Research programme: beta-amyloid inhibitors - Scios/Lilly
Latest Information Update: 01 Aug 2002
At a glance
- Originator Eli Lilly; Scios
- Mechanism of Action Amyloid beta-protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 27 Jun 2000 Preclinical development for Alzheimer's disease in USA (Unknown route)